Medtronic to acquire EPIX Therapeutics, expanding its cardiac ablation portfolio

When completed, the EPIX acquisition will expand the Medtronic cardiac ablation portfolio to offer physicians a comprehensive suite of tools to treat patients with cardiac arrhythmias.

DUBLIN: Medtronic plc recently announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular heartbeats), including atrial fibrillation (AF).

When completed, the EPIX acquisition will expand the Medtronic cardiac ablation portfolio to offer physicians a comprehensive suite of tools to treat patients with cardiac arrhythmias.

EPIX's flagship technology, the DiamondTemp(TM) ablation system, is a unique closed-loop, a temperature-controlled system that provides physicians with improved feedback and control during an ablation procedure.

The DiamondTemp system uses radiofrequency (RF) energy (heat) to create scar tissue in the heart and complements the Medtronic cryoballoon technology that uses cryo energy (cold) to isolate the pulmonary veins (PVI).

The DiamondTemp system received CE Mark in Europe in 2017 and is limited to investigational use in the U.S. The DIAMOND-AF trial, which completed enrollment in Oct. 2018, will support approval of the DiamondTemp system in the U.S. for patients with symptomatic paroxysmal AF (AF that starts and stops intermittently). Additionally, the DIAMOND-AF II trial, which is currently enrolling patients, is evaluating the Diamond Temp system in patients with persistent AF (AF that continues for long periods of time).

"The Diamond Temp ablation system stands out from other RF ablation technologies because of the real-time temperature control via rapid power modulation. This results in shorter procedure times and higher confidence in lesion quality," said Atul Verma, M.D., Southlake Regional Health Center in Newmarket, Canada, and global principal investigator for the DIAMOND-AF II study.

"I've had the pleasure of working with EPIX to design the DIAMOND-AF II trial and I look forward to continuing that work with Medtronic."

"The DiamondTemp cardiac ablation system represents leapfrog technology in the RF cardiac ablation space, a segment of the market where we haven't previously participated," said Rebecca Seidel, vice president and general manager of the Atrial Fibrillation Solutions division, which is part of the Cardiac and Vascular Group at Medtronic. "When combined with our existing leading cryoballoon technology, we expect to provide physicians with a complete portfolio of best-in-class cryo and RF systems."

The EPIX acquisition is expected to close in Medtronic's fourth fiscal quarter, which runs from January 26 to April 26, 2019, subject to the satisfaction of certain customary closing conditions. EPIX is currently pre-revenue, and although the acquisition is expected to be dilutive to Medtronic's near-term adjusted earnings per share, Medtronic intends to offset the dilution. The transaction is expected to meet Medtronic's long-term financial metrics for acquisitions. Additional terms of the transaction were not disclosed.